Mindleap ™ is designed to increase access to intellectual fitness facilities and provide intellectual fitness research to results starting with purpose setting, mood, payments and habit monitoring. The platform is flexible for end users and for specialists who need to create a profile after passing the corporate approval process It is only when an end user buys facilities on the platform that Mindleap charges a payment of 9% as a percentage of each session.
It is an exclusive technique that allows access at any time and anywhere to authorized intellectual fitness professionals, and also allows to approve specialists, set their prices, update their schedules and without delay start dealing with new customers. In addition, Mindleap users can share their knowledge of intellectual fitness with their specialist during a secure HD video call to create a more knowledge-based conversation, as intellectual fitness can be very anecdotal and difficult for others to explain. This hands-on, state-of-the-art technique, combined with an exclusive focus on psychedelic integration, adds price to end users and software use specialists.
According to Fortune Business Insights ™, the telefitness market is expected to reach a market of $560 billion through 2027, representing a compound annual expansion rate of 25. 2%. Be more than a billion telemedicine sessions until the end of 2020. La cutting-edge generation and Mindleap’s business style attempt to capture an exclusive and developing percentage of this market, starting with psychedelic integration facilities and the expansion of virtual intellectual fitness systems and other types of fitness facilities.
Mindleap Health founder and CEO Nikolai Vassev said: “It’s just that an undeniable concept has become a dynamic company with a cutting-edge generation that will soon create many satisfied customers. Our team has finished the progression of an incredibly complex formula in a short time and we our culture focuses on continuous improvement and we are already developing our complex intellectual aptitude research capabilities.
About Mindleap Health
Mindleap is a telefitness solution that helps others connect with intellectual fitness specialists who can help them thrive and expand behavior for a fit mind. The Mindleap platform provides convenience, improves access to remedies and can lead to more non-public advances. The platform is designed through clinical and neuroscientific psychologists to provide help and an un publicized remedy to each user. Our vision is global where other people can make lasting adjustments in their lives by having complex equipment and access to trained intellectual fitness professionals directly in the palm of their hands.
Watch the Mindleap platform presentation video
Apply to a Mindleap specialist
Learn more about Mindleap Health
Learn more about the beyond and long-term psychedelics as a drug
Mydecine Innovations Group ™ is a publicly traded parent company specializing in life sciences, committed to the progression and production of adaptive medicine, herbal fitness products and fungal-derived virtual fitness responses. Mydecine’s experienced multifunctional groups have the dynamic functions to monitor all drug progression spaces, addition of synthesis, genetic research, import/export, delivery formula progression, clinical trial execution, marketing and product distribution. By leveraging strategic partnerships with scientific, medical, military and clinical organizations, Mydecine is at the forefront of herbal psychedelic medicine derived from fungi, healing responses and fungal fungal energy products. Our portfolio of unified companies, adding Mydecine Health Sciences ™, Mindleap Health ™ and NeuroPharm ™ focuses on delivering cutting-edge and effective features that can provide millions of others with a higher quality of life.
For more information about Mydecine Innovations Group Inc. , see the company’s SEDAR profile on www. sedar. com or the company’s online page at www. . mydecine. com.
On behalf of the Board of Directors: Joshua Bartch, Executive Director Rcontact@mydecineinc. com
Communication Corporation: Charles Lee, Relationships Investisseurscorp@mydecineinc. com
Mindleap Health Platform Services Disclaimer: Mindleap services are designed to link users of our facilities with specialists in intellectual fitness for assistance and guidance in integrating their psychedelic delights or expanded mindfulness and translate them into positive changes. Our facilities are not designed or intended for the integration or translation of an existing psychedelic delight and do not deserve to be used for that purpose. Psychedelics are legally controlled or prohibited in many jurisdictions, however there are legal tactics to have psychedelic or conscious delight in certain circumstances. You are only guilty of properly informing yourself of the legislation of your jurisdiction at our facilities and of finding out if the use of our facilities and the reception of specialized facilities (defined below) are lawful in your jurisdiction. Our facilities are intended to be used exclusively in the context of lawful activities and must not be used in conjunction with illicit ingredients or illicit activities. Without restricting the preceding sentence, it is not legal to promote, buy, consume or sell illegal ingredients through the Services. Do not use psychedelics if it is illegal in your jurisdiction. Possession of psychedelics in violation of applicable law can result in significant penalties, adding years of incarceration.
The Canadian Stock Exchange has not dismissed or wasted the content of this press release and accepts no obligation for its adequacy or accuracy. This press release comprises forward-looking statements that relate to long-term occasions or long-term functionality and reflect existing control assumptions and expectations. These forward-looking statements reflect existing control ideals and are based on existing assumptions and data for the company. Readers are cautioned that these forward-looking statements are not promises or promises and are subject to dangers and uncertainties that could possibly cause long-term effects to differ materially from those expected, including, without limitation, the availability and continuity of financing, the ability to properly protect and enforce its intellectual property, the company’s ability to bring its products to advertising production, the continued expansion of global adaptive medicine, the herbal health care products and virtual health, and the dangers presented through the highly regulated and competitive marketplace in the development, production, sale and use of the Company’s products. Although the company has tried to identify the points on the shades that can also cause the actual effects to differ greatly from those contained in the forward-looking data, it is possible that there are other points that cause the actual effects to differ greatly. planned, estimated or planned. No assurance can be given that such data will turn out to be accurate, as actual effects and long-term occasions may also differ dramatically from those expected in such data. These forward-looking statements are made as of the date hereof and the Company assumes no legal obligation to update or revise them to reflect new occasions or circumstances, as required by applicable securities law. This press release does not constitute an offer to sell securities and the Company is not soliciting an offer to purchase securities in any jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the securities legislation of that jurisdiction. This press release does not constitute an offer to sell securities in the United States. These securities have not been and will not be registered under the United States Securities Act of 1933, as amended, or state securities law and may not be offered or sold in the United States or to anyone. United States, unless a registration exemption is registered or claimed.